Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (61-70 of 274) with videos related to

Pageof 28
Sort By:
Best Practice & Research. Clinical Haematology|December 12, 2007
The Arkansas approach to therapy of patients with multiple myelomaBart Barlogie, Elias Anaissie, Frits van Rhee, et al.
Cancer|February 27, 2008
High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patientsMauricio Pineda-Roman, Bart Barlogie, Elias Anaissie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment armsBart Barlogie, Elias Anaissie, Frits van Rhee, et al.
Clinical Epigenetics|February 4, 2023
Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogeneticsSamrat Roy Choudhury, Stephanie D Byrum, Duah Alkam, et al.
Ejhaem|June 19, 2024
B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myelomaAsis Shrestha, Marah Alzubi, Jawad Alrawabdeh, et al.
Journal of Cancer Policy|July 19, 2023
Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelinesSuhib Fahmawi, Carolina Schinke, Sharmilan Thanendrarajan, et al.
The Journal of Molecular Diagnostics : JMD|November 5, 2013
Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of lifeHoney V Reddi, Sarah Jenkins, Jason Theis, et al.
JAMA Network Open|August 26, 2022
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple MyelomaRaghad Alqazaqi, Carolina Schinke, Sharmilan Thanendrarajan, et al.
American Journal of Hematology|March 31, 2022
First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysisHassan Abushukair, Sebawe Syaj, Obada Ababneh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciencesBart Barlogie, Michel Attal, John Crowley, et al.
Pageof 28

Showing results (61-70 of 274) with videos related to

Sort By:
Pageof 28
Best Practice & Research. Clinical Haematology|December 12, 2007
The Arkansas approach to therapy of patients with multiple myelomaBart Barlogie, Elias Anaissie, Frits van Rhee, et al.
Cancer|February 27, 2008
High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patientsMauricio Pineda-Roman, Bart Barlogie, Elias Anaissie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment armsBart Barlogie, Elias Anaissie, Frits van Rhee, et al.
Clinical Epigenetics|February 4, 2023
Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogeneticsSamrat Roy Choudhury, Stephanie D Byrum, Duah Alkam, et al.
Ejhaem|June 19, 2024
B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myelomaAsis Shrestha, Marah Alzubi, Jawad Alrawabdeh, et al.
Journal of Cancer Policy|July 19, 2023
Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelinesSuhib Fahmawi, Carolina Schinke, Sharmilan Thanendrarajan, et al.
The Journal of Molecular Diagnostics : JMD|November 5, 2013
Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of lifeHoney V Reddi, Sarah Jenkins, Jason Theis, et al.
JAMA Network Open|August 26, 2022
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple MyelomaRaghad Alqazaqi, Carolina Schinke, Sharmilan Thanendrarajan, et al.
American Journal of Hematology|March 31, 2022
First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysisHassan Abushukair, Sebawe Syaj, Obada Ababneh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciencesBart Barlogie, Michel Attal, John Crowley, et al.
Pageof 28